Cathal Friel, CEO of Open Orphan (ORPH) discusses the appointment of David Kelly as an Independent Non-Executive Director on the Vox Podcast August 1, 2019 – Posted in: Open Orphan (ORPH) – Tags: AIM:ORPH, biopharma, erious diseases and rare disorders., Open Orphan, ORPH, orphan drug services, pharma stock, rare and orphan drug consulting services platform.
Cathal Friel, Chief Executive Officer of Open Orphan (ORPH) talks about the appointment to the board of David Kelly as an Independent Non-Executive Director.
Open Orphan plc is a European-focussed, rare and orphan drug consulting services platform. The Company consists of four elements: a European clinical research organisation and consultancy; an orphan drug services business; a Virtual Rep and Data Access Platform consisting of physicians and key opinion leaders; and a Health Data Platform to partner with Patient Advocacy Groups. The Company is targeting rapid growth in one of the fastest growing sectors in the global pharmaceutical industry targeting under-supplied treatment for life threatening or very serious diseases and rare disorders.